• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of pharmacometrics IND and NDA/BLA reviews completed per month (1)

Dictionary: These pharmacometrics reviews are a composite number including, but not limited to the following: a) New Drug Application (NDA) or Biologics License Application (BLA) submissions, b) Investigational New Drug (IND) protocol reviews, c) pediatric protocol reviews, d) End-of-Phase 2A (EOP2A) meetings, e) thorough QT (TQT) studies, and f) model reviews. The TQT study determines a drug's effect on cardiac repolarization.


This measure has been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A32
Nov 2009N/A34
Dec 2009N/A29
Jan 2010N/A33
Feb 2010N/A28
Mar 2010N/A37
Apr 2010N/A44
May 2010N/A25
Jun 2010N/A35
Jul 2010N/A44
Aug 2010N/A20
Sep 2010N/A32

Footnotes

  • (1) PDUFA reviews are captured by OND

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.